[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 19 of about 19
1. Bunworasate U, Arnouk H, Minderman H, O'Loughlin KL, Sait SN, Barcos M, Stewart CC, Baer MR: Erythropoietin-dependent transformation of myelodysplastic syndrome to acute monoblastic leukemia. Blood; 2001 Dec 1;98(12):3492-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Erythropoietin-dependent transformation of myelodysplastic syndrome to acute monoblastic leukemia.
  • Acute monoblastic leukemia (acute myeloid leukemia [AML], French-American-British type M5a) with leukemia cutis developed in a patient 6 weeks after the initiation of erythropoietin (EPO) therapy for refractory anemia with ringed sideroblasts.
  • AML disappeared from both marrow and skin after the discontinuation of EPO.
  • Clinical and laboratory findings were consistent with the EPO-dependent transformation of myelodysplastic syndrome (MDS) to AML.
  • It is concluded that leukemic transformation in patients with MDS treated with EPO may be EPO-dependent and that management should consist of the discontinuation of EPO followed by observation, if clinically feasible.
  • [MeSH-major] Erythropoietin / adverse effects. Leukemia, Monocytic, Acute / chemically induced. Myelodysplastic Syndromes / pathology
  • [MeSH-minor] Aged. Anemia, Sideroblastic / drug therapy. Anemia, Sideroblastic / pathology. Antigens, CD13 / analysis. Antigens, CD45 / analysis. Bone Marrow / pathology. Flow Cytometry. Humans. Male. Receptors, Erythropoietin / analysis. Skin / pathology


2. Takahashi T, Tsukuda H, Kimura H, Yoshimoto M, Tsujisaki M: Extramedullary relapse of AML with t(9;11)(p22;q23) associated with clonal evolution from trisomy 8 into tetrasomy 8. Intern Med; 2010;49(5):447-51
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extramedullary relapse of AML with t(9;11)(p22;q23) associated with clonal evolution from trisomy 8 into tetrasomy 8.
  • This report describes a patient with extramedullary relapse of acute myeloid leukemia (AML) without involving bone marrow.
  • A 57-year-old man was diagnosed as having acute monoblastic leukemia with t(9;11)(p22;q23) and trisomy 8.
  • To our knowledge, this is the first case report of clonal evolution associated with the development of myeloid sarcoma as a relapse in AML.
  • [MeSH-major] Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, Pair 8 / genetics. Chromosomes, Human, Pair 9 / genetics. Leukemia, Myeloid, Acute / genetics. Sarcoma, Myeloid / diagnosis. Sarcoma, Myeloid / genetics. Trisomy / genetics
  • [MeSH-minor] Chromosome Aberrations. Drug Therapy. Forearm. Humans. Male. Middle Aged. Recurrence. Thigh

  • Genetic Alliance. consumer health - Chromosome 9, Trisomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20190481.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


3. Saito B, Nakamaki T, Nakashima H, Usui T, Hattori N, Kawakami K, Tomoyasu S: Reversible posterior leukoencephalopathy syndrome after repeat intermediate-dose cytarabine chemotherapy in a patient with acute myeloid leukemia. Am J Hematol; 2007 Apr;82(4):304-6
Hazardous Substances Data Bank. CYTARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reversible posterior leukoencephalopathy syndrome after repeat intermediate-dose cytarabine chemotherapy in a patient with acute myeloid leukemia.
  • Acute monoblastic leukemia was diagnosed.
  • No infiltration of leukemia cells was seen.
  • These details suggest not only that direct cerebral neurotoxicity of cytarabine but also that some type of allergic response may have been involved in the development of RPLS.
  • [MeSH-major] Antimetabolites, Antineoplastic / adverse effects. Brain Diseases / chemically induced. Cytarabine / adverse effects. Leukemia, Monocytic, Acute / drug therapy. Neurotoxicity Syndromes / etiology
  • [MeSH-minor] Drug Hypersensitivity. Humans. Male. Middle Aged. Syndrome

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16947320.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine
  •  go-up   go-down


Advertisement
4. Bairey O, Kirgner I, Yakobi M, Hamdan A, Ben-Ari Z, Shaklai M: Clinical severe hepatic venoocclusive disease during induction treatment of acute monoblastic leukemia managed with defibrotide. Am J Hematol; 2002 Apr;69(4):281-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical severe hepatic venoocclusive disease during induction treatment of acute monoblastic leukemia managed with defibrotide.
  • Hepatic venoocclusive disease (VOD) is the most common complication of cytoreductive therapy used for stem cell transplantation, but it is rarely encountered during induction treatment of acute leukemia.
  • We describe a patient in whom severe clinical VOD developed shortly after induction treatment for acute monoblastic leukemia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Fibrinolytic Agents / therapeutic use. Hepatic Veno-Occlusive Disease / chemically induced. Hepatic Veno-Occlusive Disease / drug therapy. Leukemia, Monocytic, Acute / drug therapy. Polydeoxyribonucleotides / therapeutic use

  • Genetic Alliance. consumer health - Acute Monoblastic Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley-Liss, Inc.
  • (PMID = 11921023.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fibrinolytic Agents; 0 / Polydeoxyribonucleotides; 04079A1RDZ / Cytarabine; 438HCF2X0M / defibrotide; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


5. Prayongratana K, Kulpraneet M, Panichchob P, Tantisiriwat W: Acute monoblastic leukemia with t(10;11)(p12;q23) presenting with pulmonary involvement: a case report and literature review. J Med Assoc Thai; 2008 Apr;91(4):559-63
Hazardous Substances Data Bank. CASPOFUNGIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute monoblastic leukemia with t(10;11)(p12;q23) presenting with pulmonary involvement: a case report and literature review.
  • A forty-three-year-old Thai man presented with acute fever and dyspnea for one week with bilateral patchy infiltration, pancytopenia with monoblast.
  • Bone marrow study was consistent with acute monoblastic leukemia.
  • Lung lesions rapidly progressed to acute respiratory failure, which required intubation.
  • Bronchoscopy with bronchoalveolar lavage revealed monotonous monoblast infiltration.
  • Invasive pulmonary aspergillosis was suspected and successfully treated with antifungal agent.
  • This may be due to the low incidence of leukemic infiltration of acute leukemia patients, which is 0.48% and 3.06% in acute myeloid leukemia and acute monoblastic leukemia, respectively.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia, Monocytic, Acute / pathology. Lung Neoplasms / secondary
  • [MeSH-minor] Adult. Antibiotics, Antineoplastic / therapeutic use. Antifungal Agents / therapeutic use. Antimetabolites, Antineoplastic / therapeutic use. Aspergillosis, Allergic Bronchopulmonary / pathology. Bronchoalveolar Lavage. Cytarabine / therapeutic use. Echinocandins / therapeutic use. Humans. Idarubicin / therapeutic use. Male. Pyrimidines / therapeutic use. Thailand. Triazoles / therapeutic use. Voriconazole

  • Genetic Alliance. consumer health - Acute Monoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18556867.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antifungal Agents; 0 / Antimetabolites, Antineoplastic; 0 / Echinocandins; 0 / Pyrimidines; 0 / Triazoles; 04079A1RDZ / Cytarabine; F0XDI6ZL63 / caspofungin; JFU09I87TR / Voriconazole; ZRP63D75JW / Idarubicin
  • [Number-of-references] 22
  •  go-up   go-down


6. Demircioğlu F, Oren H, Yilmaz S, Arslansoyu S, Eren S, Irken G: Chemotherapy-induced acral erythema in a pediatric patient with acute monoblastic leukemia. Pediatr Hematol Oncol; 2008 Apr-May;25(3):211-5
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy-induced acral erythema in a pediatric patient with acute monoblastic leukemia.
  • Chemotherapy-induced acral erythema or palmoplantar erythrodysesthesia syndrome is a well-defined reaction to some of the chemotherapeutic agents such as methotrexate, cytarabine, doxorubicin, fluorouracil, and bleomycin.
  • The authors present a case of acral erythema in a young patient with acute monoblastic leukemia to emphasize this high-dose chemotherapy-induced side effect, which is rarely seen in children and is usually self-limited.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Erythema / chemically induced. Leukemia, Monocytic, Acute / complications

  • Genetic Alliance. consumer health - Acute Monoblastic Leukemia.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18432504.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 11056-06-7 / Bleomycin; 80168379AG / Doxorubicin; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


7. Yamada R, Horikawa K, Ishihara S, Hoshino K, Kawaguchi T, Iyama K, Mitsuya H, Asou N: Successful treatment of Aspergillus liver abscesses in a patient with acute monoblastic leukemia using combination antifungal therapy including micafungin as a key drug. Int J Hematol; 2010 May;91(4):711-5
MedlinePlus Health Information. consumer health - Hepatitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of Aspergillus liver abscesses in a patient with acute monoblastic leukemia using combination antifungal therapy including micafungin as a key drug.
  • In intensive chemotherapy for leukemia, invasive aspergillosis resulting in death is infrequently observed.
  • In such cases, aggressive diagnostic and therapeutic intervention is required.
  • Herein, we report a case of Aspergillus liver abscesses in a patient with acute monoblastic leukemia.
  • Therefore, our clinical experience suggests that the serum test is useful for the rapid diagnosis of invasive aspergillosis, especially in deep tissues, and that combination antifungal therapy with micafungin should be considered when initial monotherapy for fungal infection shows an insufficient effect.
  • [MeSH-major] Antifungal Agents / administration & dosage. Aspergillosis / drug therapy. Echinocandins / administration & dosage. Hepatitis / drug therapy. Leukemia, Monocytic, Acute / complications. Lipopeptides / administration & dosage. Liver Abscess / drug therapy
  • [MeSH-minor] Drug Therapy, Combination. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Acute Monoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Aspergillosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Infect Dis. 2008 Feb 1;46(3):327-60 [18177225.001]
  • [Cites] N Engl J Med. 1999 Mar 11;340(10):764-71 [10072411.001]
  • [Cites] Ann Pharmacother. 2001 Jun;35(6):720-9 [11408991.001]
  • [Cites] Ann Hematol. 1997 Jul-Aug;75(1-2):9-16 [9322678.001]
  • [Cites] Acta Biomed. 2006;77 Suppl 2:10-3 [16918060.001]
  • [Cites] Cancer. 2007 Dec 15;110(12 ):2740-6 [17941026.001]
  • [Cites] J Clin Microbiol. 2004 Jun;42(6):2733-41 [15184460.001]
  • [Cites] Clin Vaccine Immunol. 2008 Oct;15(10):1625-8 [18667632.001]
  • [Cites] Haematologia (Budap). 2001;31(1):73-80 [11345409.001]
  • [Cites] Clin Infect Dis. 2008 Mar 15;46(6):878-85 [18260755.001]
  • [Cites] J Infect. 2006 Nov;53(5):337-49 [16678903.001]
  • [Cites] Lancet. 2003 Oct 4;362(9390):1142-51 [14550704.001]
  • [Cites] Haematologica. 2006 Aug;91(8):1068-75 [16885047.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):1025-32 [12569602.001]
  • [Cites] Cancer. 1975 Dec;36(6):2271-6 [1060508.001]
  • [Cites] Drug Resist Updat. 2003 Aug;6(4):197-218 [12962685.001]
  • [Cites] Clin Infect Dis. 2007 Feb 15;44(4):531-40 [17243056.001]
  • [Cites] J Pediatr Hematol Oncol. 2003 Sep;25(9):732-4 [12972810.001]
  • [Cites] Clin Infect Dis. 2002 Jan 1;34(1):7-14 [11731939.001]
  • [Cites] Haematologica. 2001 Aug;86(8):862-70 [11522544.001]
  • [Cites] Clin Pharmacokinet. 2006;45(7):649-63 [16802848.001]
  • [Cites] Clin Infect Dis. 2000 Nov;31(5):1253-7 [11073760.001]
  • [Cites] J Clin Pharmacol. 2005 Oct;45(10):1145-52 [16172179.001]
  • [Cites] J Clin Pathol. 1960 Sep;13:396-413 [13707576.001]
  • [Cites] Clin Infect Dis. 2004 Sep 15;39(6):797-802 [15472810.001]
  • [Cites] J Infect Dis. 2006 Oct 1;194(7):1008-18 [16960790.001]
  • [Cites] Ann Hematol. 2006 Sep;85(9):621-3 [16758192.001]
  • [Cites] Am J Hematol. 2001 Dec;68(4):231-6 [11754411.001]
  • [Cites] Clin Infect Dis. 2003 Mar 1;36(5):630-7 [12594645.001]
  • (PMID = 20352380.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Echinocandins; 0 / Lipopeptides; R10H71BSWG / micafungin
  •  go-up   go-down


8. Crews KR, Wimmer PS, Hudson JQ, Howard SC, Ribeiro RC, Razzouk BI: Pharmacokinetics of 2-chlorodeoxyadenosine in a child undergoing hemofiltration and hemodialysis for acute renal failure. J Pediatr Hematol Oncol; 2002 Nov;24(8):677-80
Hazardous Substances Data Bank. CLADRIBINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacokinetics of 2-chlorodeoxyadenosine in a child undergoing hemofiltration and hemodialysis for acute renal failure.
  • The authors describe the clinical course and the pharmacokinetics of 2-CdA in a child with acute monoblastic leukemia who experienced acute renal failure during treatment with cytarabine and 2-CdA.
  • The average clearance rate, reflecting systemic clearance and clearance by continuous venovenous hemofiltration and hemodialysis, was 12.4 L/hour per m for the first 3 days of 2-CdA therapy.
  • Because high 2-CdA plasma concentrations were observed in this patient, clinicians are advised to exercise caution when using this drug in patients with renal dysfunction.
  • [MeSH-major] Acute Kidney Injury / metabolism. Antimetabolites, Antineoplastic / pharmacokinetics. Cladribine / pharmacokinetics. Hemofiltration. Leukemia, Monocytic, Acute / drug therapy. Renal Dialysis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / pharmacokinetics. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Aspergillosis / complications. Child. Combined Modality Therapy. Cytarabine / administration & dosage. Cytarabine / adverse effects. Daunorubicin / administration & dosage. Etoposide / administration & dosage. Fatal Outcome. Humans. Leukapheresis. Male. Metabolic Clearance Rate. Recombinant Proteins / therapeutic use. Remission Induction. Urate Oxidase / therapeutic use

  • MedlinePlus Health Information. consumer health - Dialysis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12439044.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 21765
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Recombinant Proteins; 04079A1RDZ / Cytarabine; 47M74X9YT5 / Cladribine; 6PLQ3CP4P3 / Etoposide; EC 1.7.3.3 / Urate Oxidase; ZS7284E0ZP / Daunorubicin; DAV regimen
  •  go-up   go-down


9. Walter R, Schoedon G, Bächli E, Betts DR, Hossle JP, Calandra T, Joller-Jemelka HI, Fehr J, Schaffner A: Establishment and characterization of an arsenic-sensitive monoblastic leukaemia cell line (SigM5). Br J Haematol; 2000 May;109(2):396-404
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment and characterization of an arsenic-sensitive monoblastic leukaemia cell line (SigM5).
  • Few human monoblastic cell lines have been characterized to date.
  • We have established the SigM5 cell line from a patient with acute monoblastic leukaemia (FAB M5a).
  • SigM5 monoblasts were sensitive to arsenic trioxide (As2O3) previously not described to induce apoptosis in monoblastic cells.
  • Differing considerably in morphology, immunophenotype and sensitivity to arsenics from the widely used cell lines U937, HL-60 and THP-1, SigM5 is a new monoblastic cell line useful for studying leukaemogenesis, monocyte differentiation and tumour cell susceptibility to arsenic compounds.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Arsenicals / pharmacology. Cell Culture Techniques / methods. Leukemia, Monocytic, Acute / pathology. Leukocytes, Mononuclear / pathology. Oxides / pharmacology
  • [MeSH-minor] Apoptosis / drug effects. Cell Differentiation. Cell Line / immunology. Cell Line / pathology. Chromosomes, Human, Pair 8. Humans. Karyotyping. Microscopy, Electron. Polyploidy

  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10848831.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Oxides; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


10. McCollum A, Bigelow CL, Elkins SL, Hardy CL, Files JC: Unusual skin lesions in chronic myelomonocytic leukemia. South Med J; 2003 Jul;96(7):681-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual skin lesions in chronic myelomonocytic leukemia.
  • Chronic myelomonocytic leukemia (CMML) is a relatively rare, heterogeneous syndrome classified as a myelodysplastic syndrome according to the French-American-British classification system.
  • The patient's presenting symptom was a pigmented skin nodule that, although common for cases of acute monoblastic leukemia, is peculiar for CMML.
  • This case should increase awareness of the inclusion of CMML in the differential diagnosis of a discolored nodule and highlight the clinicopathologic considerations and therapeutic challenges consistent with the diagnosis of CMML.
  • [MeSH-major] Facial Neoplasms / diagnosis. Leukemia, Myelomonocytic, Chronic / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Bone Marrow / pathology. Diagnosis, Differential. Disease Progression. Drug Resistance, Neoplasm. Face. Humans. Male. Middle Aged. Skin / pathology

  • Genetic Alliance. consumer health - Chronic Myelomonocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12940320.001).
  • [ISSN] 0038-4348
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


11. Ondrousková E, Povolná K, Vána P, Benes P, Konecná H, Zdráhal Z, Smarda J: A proteomic analysis of protein variations during differentiation of v-myb-transformed monoblasts. Leuk Res; 2007 Feb;31(2):221-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • v-myb oncogene of avian myeloblastosis virus (AMV) transforms myelomonocytic cells in vitro and induces acute monoblastic leukemia in vivo.
  • In this study, we used proteomics-based approach to identify proteins with variable expression in differentiated BM2 cells.
  • Proteome variations induced by TPA and TSA were compared to examine the mechanism of differentiation-promoting effects of these drugs.
  • We found that expression of several proteins participating in cell cytoskeleton rearrangement, heat shock response, proteosynthesis and cell signaling was altered in TPA- or TSA-treated cells.
  • We present here the first comparative proteome analysis of v-myb-transformed monoblasts BM2 focused on identification of proteins involved in their terminal differentiation.
  • [MeSH-major] Cell Differentiation / physiology. Monocytes / physiology. Oncogene Proteins v-myb / physiology. Proteins / analysis. Proteomics / methods
  • [MeSH-minor] Animals. Avian Myeloblastosis Virus / physiology. Cell Line, Transformed. Chickens. Electrophoresis, Gel, Two-Dimensional / methods. Hydroxamic Acids / pharmacology. Mass Spectrometry / methods. Phorbol Esters / pharmacology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16930693.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hydroxamic Acids; 0 / Oncogene Proteins v-myb; 0 / Phorbol Esters; 0 / Proteins; 3X2S926L3Z / trichostatin A
  •  go-up   go-down


12. Pogrebniak A, Hasmann M, Schemainda I, Pelka-Fleischer R, Nuessler V: Cytoprotective features of selenazofurin in hematopoietic cells. Int J Clin Pharmacol Ther; 2002 Aug;40(8):368-75
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The therapeutic potential of modulating intracellular NAD levels and activity of NAD-dependent enzymes by concomitant administration of conventional anticancer agents merits further research.
  • Our aim was to investigate the cytotoxic effects of Tz and Se in hematopoietic cells and to test their ability to potentiate the effects of DNA strand-disrupting agents.
  • MATERIAL: THP-1, a cell line, derived from human acute monoblastic leukemia, was used.
  • METHODS: The WST-l test was used to detect the function of NAD(P)-dependent dehydrogenases after exposure of THP-1 cells to Tz or Se.
  • RESULTS: THP-1 cells were sensitive to cytotoxic effects of Tz and Se, with IC50 values of 2.5 x 10(-5) M for Tz and 2 x 10(-6) M for Se, as determined with the WST-1 test; 10 microM Se induced cell membrane disruption in more than 20% of THP-1 cells 48 hours after commencement of treatment, whereas the same concentration of Tz failed to increase membrane permeability.
  • Pretreatment of THP-1 cells with 0.5 - 1.5 microM Se had no effect on the time course of cell death, induced by treatment with the DNA-damaging agent 1-methyl-3-nitro-1 - nitrosoguanidinium (MNNG) for 36 hours.
  • CONCLUSIONS: Contrary to other investigations, we here demonstrate that preincubation with Se may partially protect cells from cell death induced by the alkylating agents MNNG and chlorambucil in the THP-1 cell line and in CLL lymphocytes presumably by affecting spontaneous cell death.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Organoselenium Compounds / pharmacology. Organoselenium Compounds / therapeutic use. Ribavirin / analogs & derivatives. Ribonucleosides / pharmacology. Ribonucleosides / therapeutic use
  • [MeSH-minor] Cell Death / drug effects. Cell Line. Cell Survival / drug effects. Chlorambucil / pharmacology. Dose-Response Relationship, Drug. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Monocytic, Acute / drug therapy. Methylnitronitrosoguanidine / pharmacology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CHLORAMBUCIL .
  • Hazardous Substances Data Bank. RIBAVIRIN .
  • Hazardous Substances Data Bank. N-METHYL-N'-NITRO-N-NITROSOGUANIDINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12467305.001).
  • [ISSN] 0946-1965
  • [Journal-full-title] International journal of clinical pharmacology and therapeutics
  • [ISO-abbreviation] Int J Clin Pharmacol Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoselenium Compounds; 0 / Ribonucleosides; 12H3O2UGSF / Methylnitronitrosoguanidine; 18D0SL7309 / Chlorambucil; 49717AWG6K / Ribavirin; 83705-13-9 / selenazofurin; ULJ82834RE / tiazofurin
  •  go-up   go-down


13. Chen J, Gu LJ, Ying DM: [Low dose methotrexate combined with GM-CSF induced differentiation of U937 cells]. Zhonghua Xue Ye Xue Za Zhi; 2003 Aug;24(8):430-2
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To explore the effect of methotrexate on acute monoblastic leukemia cells, and the potential role of low-dose methotrexate in the treatment of monoblastic leukemia.
  • CONCLUSION: Monoblastic leukemia might be treated with low-dose methotrexate plus GM-CSF as a differentiation induction regimen.
  • [MeSH-major] Cell Differentiation / drug effects. Granulocyte-Macrophage Colony-Stimulating Factor / pharmacology. Methotrexate / pharmacology
  • [MeSH-minor] Cell Line, Tumor. Drug Synergism. Humans. Leukemia, Monocytic, Acute / pathology. Telomerase / drug effects. Telomerase / metabolism. U937 Cells

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14642183.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor; EC 2.7.7.49 / Telomerase; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


14. Villeneuve P, Kim DT, Xu W, Brandwein J, Chang H: The morphological subcategories of acute monocytic leukemia (M5a and M5b) share similar immunophenotypic and cytogenetic features and clinical outcomes. Leuk Res; 2008 Feb;32(2):269-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The morphological subcategories of acute monocytic leukemia (M5a and M5b) share similar immunophenotypic and cytogenetic features and clinical outcomes.
  • Acute monocytic leukemia (M5) is a subtype of acute myeloid leukemia (AML) with two distinct morphologic subcategories, M5a and M5b.
  • We compared the immunophenotype, cytogenetics and clinical outcome of AML M5 with non-M5 AML and also compared M5a with M5b.
  • One hundred and twelve M5 (76 M5a, 36 M5b) and 726 non-M5 cases were identified and treated on protocols at our institution.
  • There were no significant differences in immunophenotype between M5a and M5b.
  • There was no significant difference in karyotypes between M5a and M5b.
  • The complete remission rate was 70% for AML M5 and 57% for non-M5 AML (p=0.03).
  • There was no significant difference in median overall survival or disease free survival for patients with M5 versus non-M5, M5a versus M5b.
  • Our data indicate that the prognosis of AML M5 is similar to non-M5 AML and that M5a and M5b do not differ in immunophenotype, cytogenetics or clinical outcome.
  • [MeSH-major] Leukemia, Monocytic, Acute / drug therapy. Leukemia, Monocytic, Acute / genetics. Leukemia, Monocytic, Acute / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17689610.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


15. Shima T, Yoshimoto G, Nonami A, Yoshida S, Kamezaki K, Iwasaki H, Takenaka K, Miyamoto T, Harada N, Teshima T, Akashi K, Nagafuji K: Successful treatment of parainfluenza virus 3 pneumonia with oral ribavirin and methylprednisolone in a bone marrow transplant recipient. Int J Hematol; 2008 Oct;88(3):336-40
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 42-year-old woman diagnosed with acute myelogenous leukemia (FAB M5a) in first complete remission underwent allogeneic bone marrow transplantation from an HLA-matched unrelated donor in May 2006.
  • [MeSH-major] Anti-Inflammatory Agents / administration & dosage. Antiviral Agents / administration & dosage. Bone Marrow Transplantation. Methylprednisolone / administration & dosage. Parainfluenza Virus 3, Human. Pneumonia, Viral / drug therapy. Respirovirus Infections / drug therapy. Ribavirin / administration & dosage
  • [MeSH-minor] Administration, Oral. Adult. Female. Humans. Leukemia, Myeloid, Acute / therapy. Transplantation, Homologous

  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RIBAVIRIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Infect Dis. 2000 Dec;31(6):1516-8 [11096028.001]
  • [Cites] J Heart Lung Transplant. 2005 Mar;24(3):343-6 [15737764.001]
  • [Cites] Biol Blood Marrow Transplant. 2001;7 Suppl:8S-10S [11777103.001]
  • [Cites] J Infect. 2004 Nov;49(4):262-73 [15474623.001]
  • [Cites] J Fam Pract. 1993 Aug;37(2):165-70 [8336098.001]
  • [Cites] Mayo Clin Proc. 1998 Feb;73(2):153-6 [9472999.001]
  • [Cites] Pharmacotherapy. 2003 Dec;23(12):1545-9 [14695034.001]
  • [Cites] Blood. 2001 Aug 1;98(3):573-8 [11468152.001]
  • [Cites] Transplantation. 2003 Jul 15;76(1):142-6 [12865800.001]
  • [Cites] Clin Microbiol Rev. 1994 Apr;7(2):265-75 [8055470.001]
  • [Cites] Respirology. 2006 Jul;11(4):437-41 [16771913.001]
  • [Cites] Biol Blood Marrow Transplant. 2001;7 Suppl:11S-15S [11777098.001]
  • [Cites] Clin Infect Dis. 2001 Feb 1;32(3):413-8 [11170949.001]
  • [Cites] Br J Haematol. 2002 Dec;119(4):1125-32 [12472597.001]
  • [Cites] Drugs. 2007;67(10):1411-27 [17600390.001]
  • [Cites] Respir Care. 2007 Jan;52(1):59-63 [18330040.001]
  • [Cites] Clin Pharmacol Ther. 1991 Oct;50(4):442-9 [1680594.001]
  • [Cites] Clin Pharmacol Ther. 1987 May;41(5):546-55 [3568539.001]
  • [Cites] Clin Infect Dis. 1996 Nov;23(5):1033-7 [8922798.001]
  • [Cites] Med Mal Infect. 2007 Sep;37(9):605-8 [17306485.001]
  • [Cites] Bone Marrow Transplant. 2000 Nov;26(10):1097-102 [11108309.001]
  • [Cites] N Engl J Med. 1990 Nov 22;323(21):1451-7 [2233917.001]
  • [Cites] Eur J Haematol. 2002 Jul;69(1):54-7 [12270063.001]
  • [Cites] Eur J Epidemiol. 1999 May;15(5):475-84 [10442474.001]
  • [Cites] Medicine (Baltimore). 2006 Sep;85(5):278-87 [16974212.001]
  • [Cites] Pediatrics. 2002 Jul;110(1 Pt 1):e9 [12093990.001]
  • [Cites] N Engl J Med. 1992 Apr 2;326(14):921-6 [1311800.001]
  • [Cites] Bone Marrow Transplant. 1997 May;19(9):905-8 [9156264.001]
  • [Cites] Antimicrob Agents Chemother. 1999 Oct;43(10):2451-6 [10508023.001]
  • (PMID = 18712461.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antiviral Agents; 49717AWG6K / Ribavirin; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


16. Shimura K, Shimazaki C, Okano A, Hatsuse M, Okamoto A, Takahashi R, Hirai H, Sumikuma T, Ashihara E, Inaba T, Fujita N, Yasuda J, Nakagawa M: [Therapy-related myeloid leukemia following platinum-based chemotherapy for ovarian cancer]. Rinsho Ketsueki; 2001 Feb;42(2):99-103
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapy-related myeloid leukemia following platinum-based chemotherapy for ovarian cancer].
  • A 40-year-old woman, who had suffered from AML (M1) in 1983, developed ovarian cancer (stage IIIc) in December 1996 after long-term remission.
  • The patient was diagnosed as having AML (M5a), and received induction therapy consisting of IDR and Ara-C, which led to complete remission.
  • As she had not received etoposide, this case was thought to have been therapy-related leukemia due to the platinum agents used for treating the ovarian cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / adverse effects. Cisplatin / adverse effects. Doxorubicin / analogs & derivatives. Leukemia, Myeloid / etiology. Neoplasms, Second Primary / etiology. Ovarian Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11280924.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; D58G680W0G / pirarubicin; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 11
  •  go-up   go-down


17. Classen CF, Teigler-Schlegel A, Röttgers S, Reinhardt D, Döhner K, Debatin KM: AML bearing the translocation t(11;17)(q23;q21): involvement of MLL and a region close to RARA, with no differentiation response to retinoic acid. Ann Hematol; 2005 Nov;84(12):774-80
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AML bearing the translocation t(11;17)(q23;q21): involvement of MLL and a region close to RARA, with no differentiation response to retinoic acid.
  • We describe a case of acute myeloid leukemia (AML) bearing the translocation t(11;17)(q23;q21).
  • The morphological phenotype represented a monoblastic leukemia, AML French-American-British (FAB) M5a.
  • Further analysis of the translocation revealed an involvement of the mixed-lineage leukemia (MLL) gene and a region closely proximal to the retinoic acid (RA) receptor alpha (RARA) gene.
  • Rearrangements of the MLL (11q23) gene in AML are usually related to the morphological phenotype FAB M5.
  • In general, they are associated with an adverse prognosis.
  • In acute promyelocytic leukemia, the translocation (15;17)(q22;q11-21) involving the RARA leads to a maturation arrest that can be overcome by RA, often inducing remission.
  • In other forms of AML, however, the effects of RA are limited and diverse.
  • To study whether RA might have a therapeutical potential in our case, we performed an in vitro analysis of RA effects on AML cells.
  • Our data indicate that in AML cells bearing the t(11;17)(q23;q21), a differentiation arrest that is overcome by RA is not present.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Cell Differentiation / drug effects. Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, Pair 17 / genetics. Leukemia, Myeloid, Acute / genetics. Translocation, Genetic. Tretinoin / pharmacology
  • [MeSH-minor] Antigens, CD38 / biosynthesis. Cell Death / drug effects. Cell Death / genetics. Child. Drug Screening Assays, Antitumor. Female. Gene Expression Regulation, Leukemic / drug effects. Gene Expression Regulation, Leukemic / genetics. Hematopoietic Stem Cells / metabolism. Hematopoietic Stem Cells / pathology. Histone-Lysine N-Methyltransferase. Humans. Myeloid-Lymphoid Leukemia Protein / genetics. Myeloid-Lymphoid Leukemia Protein / metabolism. Proto-Oncogene Proteins c-kit / biosynthesis. Receptors, Retinoic Acid / genetics. Receptors, Retinoic Acid / metabolism. Receptors, Retinoic Acid / therapeutic use. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16044313.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / MLL protein, human; 0 / Receptors, Retinoic Acid; 0 / retinoic acid receptor alpha; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; 5688UTC01R / Tretinoin; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 3.2.2.5 / Antigens, CD38
  •  go-up   go-down


18. Reddy KS, Parsons L, Wang S, Mak L, Dighe P, Yu TL: FISH analysis of an AML-M5a with segmental rearrangements involving 11q23-MLL region. Cancer Genet Cytogenet; 2000 Apr 1;118(1):48-51

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FISH analysis of an AML-M5a with segmental rearrangements involving 11q23-MLL region.
  • Recently, his condition deteriorated and he was found to have 68% blasts in the blood and AML-M5a.
  • [MeSH-major] Chromosome Aberrations / genetics. Chromosomes, Human, Pair 11 / genetics. In Situ Hybridization, Fluorescence. Leukemia, Monocytic, Acute / genetics. Proto-Oncogenes. Transcription Factors
  • [MeSH-minor] Aged. Child, Preschool. DNA-Binding Proteins / genetics. Female. Gene Amplification / genetics. Histone-Lysine N-Methyltransferase. Humans. Male. Middle Aged. Myeloid-Lymphoid Leukemia Protein. Thrombocytosis / drug therapy. Thrombocytosis / genetics. Thrombocytosis / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10731590.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / MLL protein, human; 0 / Transcription Factors; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  • [Number-of-references] 3
  •  go-up   go-down


19. Kim A, Cook R, Wainwright L, Biegel J, Schuster S, Wasik M: Dramatic response of acute monoblastic leukemia to a single dose of docetaxel. Leuk Lymphoma; 2008 Mar;49(3):577-80
Hazardous Substances Data Bank. DOCETAXEL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dramatic response of acute monoblastic leukemia to a single dose of docetaxel.
  • [MeSH-major] Leukemia, Monocytic, Acute / drug therapy. Neoplasms, Second Primary / drug therapy. Taxoids / therapeutic use

  • Genetic Alliance. consumer health - Acute Monoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18297537.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel
  •  go-up   go-down






Advertisement